Golidocitinib Combined With Selinexor for CAEBVD

NCT07369739

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Beijing Friendship Hospital
Enrollment	28 participants

Key Eligibility Criteria

Inclusion (8)

- CAEBVD diagnosed in accordance with the Consensus on the Diagnosis and Treatment of Chronic Active Epstein-Barr Virus Disease (2025 Edition).
- Aged e 18 years and d 70 years, regardless of gender.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Before the initiation of the study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) d 3 × upper limit of normal (ULN); total bilirubin d 2 × ULN; serum creatinine d 1.5 × ULN.
- Routine blood test: absolute neutrophil count e 1 × 10#/L; platelet count e 50 × 10#/L; hemoglobin e 60 g/L.

... and 3 more (see full listing online)

Exclusion (12)

- Evidence of EBV-associated hematological diseases or malignancies, such as hemophagocytic lymphohistiocytosis, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, non-Hodgkin's lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, and gastric cancer.
- Having received any of the following treatments: prior treatment with any JAK inhibitor; administration of any investigational drug within 12 weeks prior to the first dose of the study drug; concurrent enrollment in another clinical study.
- A history of other primary malignancies within 5 years prior to the first dose of the study drug, excluding locally curable malignancies that have received curative treatment (e.g., basal or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast).
- A history of organ transplantation (e.g., liver transplantation, kidney transplantation).
- Planned hematopoietic stem cell transplantation during the study period.

... and 7 more (see full listing online)

Locations (1 total)

Beijing Friendship Hospital, Beijing, China